COURTNEY D'ANNUNZIO: Open Payments
NPI 1871221028 · COLUMBUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$545 in 25 payments from 13 companies in 2025. Trend: 2023 $207 · 2024 $268 · 2025 $545
Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $255 |
| Astellas Pharma US Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: Ozempic, Veozah, Wegovy, REXULTI, CAPLYTA, FANAPT, AIRSUPRA, QULIPTA.
Industry payments across NJ — which companies pay providers there.
